Effect of specimen type on free immunoglobulin light chains analysis on the Roche Diagnostics cobas 8000 analyzer
Open Access
- 8 December 2015
- journal article
- research article
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 1-9
Abstract
The measurement of free immunoglobulin light chains is typically performed on serum; however, the use of alternative specimen types has potential benefits. Using the Freelite™ kappa and lambda free light chains assay on a Roche Diagnostics cobas 8000 c502 analyzer, we compared three specimen types (serum, EDTA-plasma and lithium heparin plasma separator gel-plasma) on 100 patients. Using Deming regression and eliminating outliers (limiting data to light chain concentrations below 400 mg/L), the three specimen types showed comparable results for kappa light chain concentration, lambda light chain concentration, and kappa/lambda ratio with slopes close to 1.0 and y-intercepts close to zero. EDTA-plasma showed slightly more positive bias relative to serum than lithium heparin. Analysis using EDTA-plasma and lithium heparin plasma showed comparable linearity, precision, and temperature stability. A single sample showing hook effect (not in the comparison set) gave comparable results using either plasma specimen type. For the Freelite™ kappa and lambda free light chains assay, both EDTA-plasma or lithium heparin-plasma can serve as acceptable substitutes for serum, at least for the Roche cobas 8000 analyzer.Keywords
This publication has 26 references indexed in Scilit:
- Serum free light chain reference values: A critical approachClinical Biochemistry, 2013
- Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditionsTherapeutic Advances in Hematology, 2012
- Clinical and preclinical validation of the serum free light chain assay: identification of the critical difference for optimized clinical useEuropean Journal of Haematology, 2012
- Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Blood, 2011
- Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort studyThe Lancet, 2010
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disordersLeukemia, 2008
- Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging systemLeukemia, 2008
- Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosisInternal Medicine Journal, 2007
- Diagnostic Performance of Quantitative κ and λ Free Light Chain Assays in Clinical PracticeClinical Chemistry, 2005
- Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapyBritish Journal of Haematology, 2003